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Pancreatic ductal adenocarcinoma (PDA) is the most common form of pancreas cancer. Because 
PDA is notoriously resistant to chemotherapy and often diagnosed after the disease has spread, it 
carries a very poor prognosis with less than 20 percent of patients surviving past twelve months after 
diagnosis. A new Fred Hutch study led by former graduate student Dr. Justin Mirus in the labs of Dr. 
Sunil Hingorani (Clinical Research and Public Health Sciences Divisions) and Dr. Paul Lampe 
(Human Biology and Public Health Sciences Divisions), addressed some of these challenges by 
applying a pancreas cancer-tailored, high-density antibody microarray to a mouse model of PDA, to 
uncover novel candidate biomarkers. "Developing better strategies for early detection of the disease 
at potentially curable stages is confounded by the difficulties in identifying the appropriate 
experimental population", explained Dr. Hingorani. 
The authors had previously developed a mouse model of PDA that employed conditional, pancreas-
specific expression of mutant forms of the Kras oncogene and the Trp53 tumor suppressor (known 
as the KPC model). This model had been shown to recapitulate many aspects of the human disease 
(Hingorani et al., 2005). "Interrogating samples from these models at histologically defined stages of 
preinvasive and invasive disease with a tailored, high-density antibody array platform developed by 
Dr. Paul Lampe, provided a unique opportunity to identify clinically meaningful biomarkers for this 
disease", said Dr. Hingorani. As mentioned above, the authors first developed a custom antibody 
microarray with over 2,500 antibodies that targeted proteins known to be involved in PDA 
pathogenesis, as well as proteins with a wide range of functions. Next, the investigators interrogated 
this antibody microarray platform with pancreata from KPC and control mice at 2 and 4 months of 
age. The 2-month old mice represented early stage disease while the 4-month old mice were 
characterized by preinvasive as well as invasive PDA. Overall, 71 proteins distinguished KPC 
pancreatic tissue from normal pancreas. Cross-referencing the 71 proteins with a pancreas cancer 
biomarker database revealed that 42 of these had been previously implicated in pancreas cancer, 
whereas the remaining 29 represented novel potential biomarkers. To validate these markers, the 
authors focused on a set of 16 proteins that were highly upregulated in KPC tissue and found that 7 
could be validated by immunoblotting. Importantly, 6 out of the 7 novel biomarkers distinguished 
KPC mice from mice harboring chronic pancreatitis. For the remainder of the study, the authors 
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further characterized the spatiotemporal expression of one of the protein markers, the 
serine/threonine kinase STK4. This immunohistochemical analysis showed that STK4 expression 
increased from 2-month to 4-month disease and then plateaued, suggesting a potential role for 
STK4 in the progression from early stage disease to PDA. Finally, the authors queried human tissue 
microarrays from 25 human PDA and 8 non-disease controls, and found that STK levels indeed 
increased in human PDA. 
In summary, this study combined a faithful model of PDA with a custom antibody microarray, to 
identity and validate 7 novel PDA candidate biomarkers, and further characterized STK4 as a marker 
of human PDA. While the function of STK4 in PDA progression is currently unknown, "the kinase 
identified in this case may also serve as a therapeutic target, an additional avenue that is being 
explored", added Dr. Hingorani. 
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Schematic of an antibody microarray protocol. Protein 
lysates from mice with pancreatic cancer (KPC) and from 
normal pancreata are incubated on a pancreas cancer-
tailored antibody microarray. Computational analysis of 
proteins elevated in KPC relative to controls uncovers 
candidate biomarkers. 
 
